Patrik Brundin MD PhD (@brundinpatrik) 's Twitter Profile
Patrik Brundin MD PhD

@brundinpatrik

MD PhD, Therapeutic Area Leader for Movement disorders at @Roche Expert on #Parkinson and #Huntington disease. Views expressed here are my own.

ID: 1055781427948732416

calendar_today26-10-2018 11:21:22

11,11K Tweet

3,3K Followers

872 Following

The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

Researchers review metabolomics in #Parkinsons, exploring alteration of metabolites in the TCA cycle, pentose phosphate pathway, kynurenic network, & redox system mdpi.com/2218-1989/15/3


Researchers review metabolomics in #Parkinsons, exploring alteration of metabolites in the TCA cycle, pentose phosphate pathway, kynurenic network, & redox system
mdpi.com/2218-1989/15/3

Eric Topol (@erictopol) 's Twitter Profile Photo

The vaccine against Shingles helps protect against dementia, results of a natural experiment, adding to prior evidence "implications are profound" New nature nature.com/articles/s4158
 nature.com/articles/d4158


The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

Interesting: Genes associated with primary cilia, non-synaptic sensory & signaling organelles, are upregulated in cortical neurons in both early & late stage #Parkinsons patients; Tet2 loss & enhanced ciliogenesis suppress α-synuclein pathology actaneurocomms.biomedcentral.com/articles/10.11


Interesting: Genes associated with primary cilia, non-synaptic sensory & signaling organelles, are upregulated in cortical neurons in both early & late stage #Parkinsons patients; Tet2 loss & enhanced ciliogenesis suppress α-synuclein pathology
actaneurocomms.biomedcentral.com/articles/10.11

jorgenponder — om coronavirusepidemin (@jorgenponder) 's Twitter Profile Photo

Mats Melin, ordförande för Coronakommissionen och tidigare domare i Högsta domstolen, beskriver Sveriges pandemistrategi första Ă„ret. Nytt program frĂ„n UR: urplay.se/program/239265


Cure Parkinson's (@cureparkinsonst) 's Twitter Profile Photo

"We have to cure this pernicious condition, and we have never been closer to finding a cure." Catch our chairman of the charity’s development board Will Cook discussing our #walkforacure campaign: buff.ly/9ErsB8j

The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

Gain Therapeutics Gain Therapeutics researchers & collaborators report Gaucher’s fibroblasts (GBA1 variants) have increased Tau accumulation (vs control fibroblasts) & pharmacological enhancement of GCase reversed this effect; Implications for #Parkinsons? nature.com/articles/s4159


Gain Therapeutics <a href="/GainThera/">Gain Therapeutics</a> researchers &amp; collaborators report Gaucher’s fibroblasts (GBA1 variants) have increased Tau accumulation (vs control fibroblasts) &amp; pharmacological enhancement of GCase reversed this effect; Implications for #Parkinsons?
nature.com/articles/s4159

The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

A personal view on gene therapy for #Parkinsons is a timely & succinct overview of both the progress & challenges - weekend reading! thelancet.com/journals/laneu


A personal view on gene therapy for #Parkinsons is a timely &amp; succinct overview of both the progress &amp; challenges - weekend reading!
thelancet.com/journals/laneu

Krzysztof Potempa (@braincures) 's Twitter Profile Photo

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson’s Disease: The International Linked Clinical Trials Initiative—Richard Wyse, Tom Isaacs, Roger Barker, Dimitri Krainc, Simon Stott The Science of Parkinson's, Patrik Brundin MD PhD linkedin.com/posts/krzyszto


The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

Using PASADENA study data, Gennaro Pagano & Roche collaborators find that the time-to-event approach may mitigate the potential confounding effect of symptomatic therapy on MDS-UPDRS Part III in #Parkinsons clinical trials exploring disease modification nature.com/articles/s4153


Using PASADENA study data, <a href="/DrGennaroPagano/">Gennaro Pagano</a> &amp; <a href="/Roche/">Roche</a> collaborators find that the time-to-event approach may mitigate the potential confounding effect of symptomatic therapy on MDS-UPDRS Part III in #Parkinsons clinical trials exploring disease modification
nature.com/articles/s4153

The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

“Is the solution not to allow the rest of the world to publish? We live in a digital world. Surely, it doesn’t matter how many papers are being published” - Ritu Dhand The solution is to move aware from publishing in "journals". That model is long dead theguardian.com/science/2025/j


The Science of Parkinson's (@scienceofpd) 's Twitter Profile Photo

Nice editorial in the The Lancet Neurology on accelerating the path towards a cure for #Parkinsons - the michaeljfox.org "Targets to Therapies" (T2T) initiative gets a mention, as does the new Alzheimer's Research UK & Cure Parkinson's collaboration - lots of activities thelancet.com/journals/laneu


Krzysztof Potempa (@braincures) 's Twitter Profile Photo

#WorldBrainDay We believe there won't be a single silver bullet for this disease. Each patient will likely require a mix of medicines at different stages of disease, and with more options available, this precision medicine becomes possible Patrik Brundin MD PhD linkedin.com/posts/krzyszto